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Chronobiological disorders and syndromes include sea-
sonal affective disorder (SAD), total blindness, advanced
and delayed sleep phase syndrome, jet lag, and shift
work maladaptation. These disorders are treated by
adjusting circadian phase, using appropriately timed
bright light exposure and melatonin administration (at
doses of 0.5 mg or less). In some cases, it may be neces-
sary to measure internal circadian phase, using the time
when endogenous melatonin levels rise. 
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elatonin appears to be useful in two ways to the
field of human chronobiology.One role is as a marker for
biological rhythms.The other role is as a circadian phase-
shifting agent.Both roles appear to be important.
In virtually all organisms,melatonin is produced mainly
during nighttime darkness.
1,2 In most vertebrates,circu-
lating melatonin levels are derived exclusively from the
pineal gland.
3,4 In most mammals,the changing duration
of melatonin production throughout the year is the cue
for seasonal rhythms.
5 In some mammals, such as
humans,a feedback loop exists between melatonin and
the endogenous circadian pacemaker.
6-13
An approximately 24-h (hence, circadian) rhythm in
melatonin is generated by 12 h of (usually daytime) inhi-
bition of an otherwise constantly “on”signal from the
paraventricular nucleus of the hypothalamus.
14This inhi-
bition comes from the endogenous circadian pacemaker,
located in the suprachiasmatic nucleus (SCN).
15-17 The
pineal gland is then stimulated to produce melatonin for
about 12 h via a neural pathway that traverses through
the intermedullary column and thoracic sympathetic out-
flow (Figure 1).
18 Preganglionic neurons synapse in the
superior cervical ganglion with postganglionic neurons
that enter the cranium and innervate pinealocytes.
19The
latter release the sympathetic neurotransmitter,norepi-
nephrine,which stimulates β1-adrenergic receptors and
results in the synthesis and secretion of melatonin,which
is then released into blood and cerebrospinal fluid
(CSF).
20 Receptors for melatonin have been identified in
a number of sites,including the SCN.
21,22
The approximately 24-h rhythm generated by the SCN
becomes precisely 24 h via photic input from ganglion
cells in the retina.
23,24At least one novel photoreceptor
has been identified that mediates circadian entrain-
ment.
25The pathway from the retina to the hypothala-
mus,the retinohypothalamic tract,is different from that
which mediates vision.
26
MThe light/dark cycle synchronizes the SCN, and there-
fore its many driven circadian rhythms, to the 24-h
day.
27,28 Unique to melatonin,light acutely suppresses its
production.
29 Thus, if the SCN has not turned off mela-
tonin production in the morning, exposure to light will.
Also, light exposure at the end of the day will suppress
the evening rise in melatonin production.
30
These effects of light shape the melatonin profile. As
mentioned above, annual rhythms common to many
mammals receive their seasonal time cue from the chang-
ing duration of melatonin production,thought to define
the “biological night.” Whether or not humans have
important seasonal rhythms is a matter of some contro-
versy.
31,32 If humans have important seasonal rhythms,it
is thought that the duration of melatonin production
would regulate them.Not controversial is the fact that,
similar to other animals,humans have circadian rhythms
that are primarily regulated by the light/dark cycle.
30,33-38
The endogenous melatonin profile as a
marker for circadian phase position
In humans, the melatonin profile is the most reliable
marker for circadian phase (Figure 2).
39-41 The time that
melatonin levels rise appears to be a useful phase maker.
The melatonin onset (MO) is a clearly demarcated
event. It can be operationally defined in a number of
ways,some of which use a threshold (2 pg/mL,10 pg/mL,
etc), which appears as a subscript in the acronym.
42
In order to minimize the acute suppressant effect of
light,plasma samples are collected under dim light (opti-
mally, less than 30 lux). Therefore, in sighted people 
this marker is called the dim light melatonin onset
(DLMO).
43 The plasma DLMO10 occurs on average
about 14 h after waketime in entrained,sighted people,
and the DLMO2 occurs about 1 h earlier.
13,44,45
The light zeitgeber (German for time-giver,or time cue)
first occurs each day at waketime.
46 In the circadian lit-
erature,this is called zeitgeber time 0 (ZT 0).(Sometimes
the term circadian time [CT] is used under certain cir-
cumstances;although they are technically different,ZT
and CT will be used interchangeably in this monograph,
in order to minimize confusion on the part of readers
who are not experts in chronobiology.) As mentioned
above,the average CT or ZT of the plasma DLMO10 is
14 h in entrained, sighted people.The DLMO ZT also
describes the relationship between the circadian rhythms
that are tightly coupled to the SCN (such as melatonin)
and those that are more loosely coupled (such as the
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Selected abbreviations and acronyms
ASPS advanced sleep phase syndrome
BFR blind free-runner
CSD circadian sleep disorder
CT circadian time
DLMO dim light melatonin onset
DSPS delayed sleep phase syndrome
MO melatonin onset
PRC phase response curve
PSH phase shift hypothesis
SAD seasonal affective disorder
SCN suprachiasmatic nucleus
ZT  zeitgeber time
Figure 1. Schematic diagram depicting neuroanatomic regulation of
mammalian melatonin production.
Reproduced from reference 18: Vessely LH, Lewy AJ. Melatonin as a hor-
mone and as a marker for circadian phase position in humans. In: Pfaff
D, Arnold A, Etgen A, Fahrbach S, Rubin R, eds. Hormones, Brain and
Behavior, Vol 5. San Diego, Calif: Elsevier Science; 2002:121-141.
Copyright © 2002, Elsevier Science.
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intermediolateral nucleisleep/wake cycle,for example,waketime).Therefore,any
mismatch in circadian rhythms will be reflected in a ZT
that differs from the 14-h standard.
The light PRC
Light’s phase-shifting effects on circadian rhythms can
be explained by a phase response curve (PRC).Its essen-
tial features are that light exposure in the morning causes
a phase advance (shift to an earlier time) and that light
exposure in the evening causes a phase delay (shift to a
later time).
33,36,47 In addition,maximal phase shifts occur
in the middle of the night,and minimal phase shifts occur
during the middle of the day.
48-51 PRCs are usually plot-
ted according to CT. The break points that separate
advance and delay responses for the light PRC are 12 h
apart:they occur at CT 6 and CT 18.Converting to clock
time for an individual who habitually awakens at 7.00
AM, these are 1.00 PM and 1.00 AM, respectively. With
regard to the light PRC,there are several investigators
who think that these break points occur a few hours
later.
52The jury is out on this question.
As mentioned above,light is the most potent circadian
zeitgeber in virtually all organisms.However,this was not
fully appreciated in humans until it was shown that
humans require brighter light for this effect than other
animals, which was dramatically demonstrated with
respect to acute suppression of melatonin production.
53
The phase-shifting and suppressant effects of light are
thought to be closely associated.Since sunlight (10 000-
100 000 lux) is usually brighter than indoor light,humans
might be responding to the natural light/dark cycle,rela-
tively unaffected by ordinary-intensity indoor light (200-
500 lux).A second implication is that bright artificial light
could be substituted for sunlight,in order to experimen-
tally (and perhaps therapeutically) manipulate biologi-
cal rhythms in humans.
Winter depression (SAD)
One of the first therapeutic uses of bright light was to
treat winter depression, or seasonal affective disorder
(SAD).
54,55 Bright light has also been used to treat non-
seasonal depression,
56 which is reviewed elsewhere (see
Clinical applications of melatonin - Lewy  Dialogues in Clinical Neuroscience - Vol 5 . No.4 . 2003
401
Figure 2. Relationship between the endogenous melatonin profile, the melatonin phase response curve (PRC), and the sleep/wake cycle. MO, mela-
tonin onset; BFR, blind free-runner; CT, circadian time.
Adapted from reference 41: Lewy AJ, Bauer VK, Hasler BP, Kendall AR, Pires MLN, Sack RL. Capturing the circadian rhythms of free-running blind people with
0.5 mg melatonin. Brain Res. 2001;918:96-100. Copyright © 2001, Elsevier Science BV.
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The greatest phase advances occur
when exogenous melatonin is given here.Parry’s and Wirz-Justice’s contributions to this vol-
ume
57,58),as well as many of the hypotheses for SAD (see
Parry’s,Wirz-Justice’s and Praschak-Rieder’s contribu-
tions to this volume
57-59) and so these will not be covered
here.This monograph will concentrate on diagnosing cir-
cadian phase disorders using the endogenous melatonin
profile and on the basic principles for treating them.
The leading hypothesis for SAD is the phase shift
hypothesis (PSH).
33 According to the PSH, the typical
SAD patient becomes depressed in the winter,at least in
part because of a phase delay of circadian rhythms
(marked by the DLMO) with respect to sleep,
33,60,61 hav-
ing a mismatch in circadian rhythms (similar to jet lag),
which persists for several months.Therefore,bright light
exposure should be most antidepressant when it is sched-
uled in the morning,when it would be expected to cause
a corrective phase advance.Bright light exposure in the
morning should certainly be more antidepressant than
evening bright light,which would be expected to cause a
phase delay.
The first major test of the PSH was a crossover study of
eight patients and seven control subjects.
36There was a
small,but statistically significant,delay of the DLMO in
patients compared to controls at prebaseline and at the
end of the initial week of baseline conditions (sleep per-
mitted only between 10.00 PM and 6.00 AM).Two hours
of morning bright light (2500 lux) caused advances in the
DLMO;evening bright light caused delays.The combi-
nation of morning plus evening light (which was the last
treatment week) moved the DLMO towards its baseline
time.Morning light produced a significant antidepressant
effect compared with baseline and with evening light.The
combination was again intermediate between that of
morning light alone and evening light alone.This study
was by and large replicated a few years later.
62,63 Since
then,not much has changed in the recommended light
treatment regimen,except that light intensity can be as
great as 10 000 lux,
64 and perhaps 1 h per day is sufficient,
as long as it is scheduled immediately upon awakening.
Once treatment is satisfactory,the duration of light expo-
sure can almost always be reduced.
65
Several other studies have supported these findings,but
some have not
66,67: these studies were usually parallel-
designed, so that patients themselves did not have the
opportunity to compare light exposure at different times
(which would have minimized the placebo component).
In 1998, three independent research groups published
large-N studies in which morning light was shown to be
more antidepressant than evening light,thereby moving
the field towards consensus about the superiority of
morning light.
45,68,69 However,superior efficacy of morn-
ing light does not necessarily prove the PSH,because it
could be more antidepressant at this time for some rea-
son other than causing a phase advance.However,it has
been shown that the antidepressant response to morning
light does, in some circumstances, correlate with the
amount of phase advance in the DLMO.This was first
reported with respect to treatment group means,
61 fol-
lowed by an analysis
70 of individual DLMOs and depres-
sion scores collected independently.
36,63 More recently,this
latter finding was essentially replicated using another
data set.
71 Further support of the PSH along these lines
will be discussed below. It should also be noted that a
very small subgroup of SAD patients appear to be cue-
ing to dusk and should be treated with evening bright
light;clinically,these patients can be identified by a his-
tory of early morning awakening year round, going to
bed much earlier in the winter.
65
In any event,the earliest and most common use of the
DLMO has been to assess the phase-shifting effects of
light.Bright light has also been used to treat a number of
other circadian phase disorders,such as advanced sleep
phase syndrome (ASPS),delayed sleep phase syndrome
(DSPS), jet lag, and shift work maladaptation (see
below).
The melatonin PRC
The phase-shifting effects of melatonin are also described
by a PRC.The melatonin PRC is about 12 h out of phase
with the light PRC.
13,44 Both PRCs are phase-locked to
each other,as well as to the melatonin profile (Figure 2).
As mentioned above, waketime is usually designated 
ZT 0.Sleep time is therefore usually ZT 16.In the mela-
tonin PRC studies of sighted people,the baseline plasma
DLMO10 was designated CT 14. It is also designated 
CT 14 in free-running blind people.We call this phase
marker the MO in blind people.Saliva can also be used
(at this time of the night, salivary melatonin levels are
about one-third those of plasma).
72 Measuring the MO in
blind people provides a reference point to determine the
phase of the endogenous circadian pacemaker and the
melatonin PRC.Unless stated otherwise,in the follow-
ing the MO refers to the plasma 10 pg/mL threshold or
its salivary equivalent (3 pg/mL).The melatonin PRC
was first described using four daily doses of 0.5 mg mela-
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cated by two other research groups.
73,74
In sighted people who habitually awaken at 7.00 AM,the
break points that divide the two intervals of the mela-
tonin PRC occur at 1.00 PM (CT 6) and 1.00 AM (CT 18),
just as with the light PRC.The phase-advance zone is
between 1.00 AM and 1.00 PM; the phase-delay zone is
between 1.00 AM and 1.00 PM. Once again, the phase-
advance zone of the melatonin PRC extends from CT 6
to CT 18,and the phase-delay zone extends from CT 18
to CT 6.Therefore,once the time of the MO is known,
the advance zone extends from 8 h before the MO until
4 h after the MO.The delay zone extends from 4 h after
the MO until 8 h before the MO.
Treating SAD patients with melatonin: 
the importance of creating “overlap”
Creating “overlap” may be an important principle in
optimizing melatonin’s phase-shifting effects.This was
demonstrated in a pilot study treating SAD patients with
melatonin.
75 In order to avoid the soporific side effect of
sleepiness that occurs in some people,the dose of mela-
tonin is kept to a minimum, so as to reduce the initial
spike in melatonin levels following an oral,immediate-
release formulation. However, according to the mela-
tonin PRC,the earlier melatonin is given in the afternoon
(at least for the second half of the advance zone), the
greater the magnitude of the phase-advance shift.If a low
dose is given too early, however, there will be a mela-
tonin-free interval between the end of the exogenous
pulse and the beginning of the endogenous melatonin
profile that occurs about 14 h after waketime in
entrained,sighted people.Therefore,a second (or even a
third or possibly fourth) small dose of melatonin is given
to create overlap between elevated melatonin levels aris-
ing from exogenous and endogenous sources,so that the
SCN is exposed to one continuous melatonin signal.
Recently,a more definitive test of the PSH for SAD was
completed,using three to four small doses of melatonin
(0.075-0.1 mg) given every 2 h in the morning or in the
afternoon/evening.One hundred patients were studied
over four winters. One-third of them did not receive
melatonin in any capsule,although all subjects took the
same number of capsules per day.Subjects were held to
consistent bedtimes and waketimes of their choosing.
The results supported the PSH.In the most phase-delayed
group of patients (those with a DLMO ZT >14.6),there
was a significant correlation between the amount of phase
delay at baseline and the severity of depression ratings.
After 3 weeks of treatment,this correlation remained sig-
nificant,but only if depression severity was analyzed with
regard to the absolute difference from the hypothesized
“normal” ZT of 14. Change scores analyzed in this way
were also statistically significant:as DLMO ZT normal-
ized,depression ratings improved.This may be one of the
first examples of a physiological marker that correlates
with psychopathology at baseline and posttreatment.
These data are consistent with the clinical observation
that too much of a phase advance can result in a return
of symptoms.In any event,morning light appears to be
more antidepressant than evening light in typical SAD
patients,because,at least in part,it is correcting a phase
delay that occurs in SAD patients when they become
depressed in the winter.Using SAD as a model chrono-
biological psychiatric (affective) disorder,it would now
seem timely to investigate other disorders, in order to
assess the contribution of a mismatch between circadian
rhythms to the pathology.
Treating free-running totally blind 
people with melatonin: 
the importance of avoiding “spillover”
About 15% of blind people completely lack light per-
ception.Most,if not all of them,have abnormal circadian
rhythms, and many of them “free-run,” whereby their
MOs drift a little later each day.When they are out of
phase,they find it difficult to sleep at night and are tired
during the day—a burden described by some as second
only to lack of vision.A daily drift in sleep times is not
usually observed.However,assessment of physiological
rhythms clearly indicates this daily drift in the phase of
the endogenous circadian pacemaker.Any of several cir-
cadian rhythms can be measured,including cortisol and
temperature.
76-79 However,these are masked by changes
in activity.
80 Melatonin production is masked only by
light,
53 which is not an issue in blind people.
A number of studies now document circadian abnor-
malities in the totally blind population.
81-83The MO has
proved to be a useful phase marker in blind people,
whether it is extracted from 1-h samples over 24 h or
from sampling every 30 to 60 min within a narrower win-
dow when it is expected to occur. However, as will be
explained below,assessing MOs is not absolutely neces-
sary in diagnosing and treating most cases.
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403Following the discovery that light can suppress melatonin
production in humans,
53 the obvious next step was to assess
the melatonin profiles of blind people. One-day assess-
ments indicated that melatonin levels were continuously
elevated for about 12 h out of every 24 h,similar to sighted
people.
84 However, it was not always confined to night.
Two bilaterally enucleated people were studied longitudi-
nally
85:one of them appeared to be stably entrained,but
180° out of phase (that is,melatonin levels peaked in the
middle of the day,week after week);the other was free-
running with an intrinsic circadian period (tau, or τ) of 
24.7 h (that is,the endogenous melatonin profile shifted
later at a rate of about 0.7 h per day or about 5 h per
week).Several studies have since confirmed that the cir-
cadian rhythms of blind people are of three types: nor-
mally entrained,abnormally entrained,and free-running.
85
When out of phase,these individuals have difficulty sleep-
ing at night and take more naps during the day.The mela-
tonin rhythm reflects the phase of all other endogenous
circadian rhythms,including those of cortisol,temperature,
and sleep propensity (see above).
As mentioned earlier,another use of melatonin is to give
it exogenously in order to cause phase shifts.
13 Inspired
by animal studies,
86 these effects were most conclusively
demonstrated by entraining free-running blind people
(blind free-runners [BFRs]) with a daily dose of mela-
tonin.
87 Although an early subject showed apparent
entrainment to a dose of about 7 mg,
88-90 entrainment of
BFRs was conclusively demonstrated using a dose of 
10 mg.
87,91 Only one of seven BFRs failed to entrain to the
10-mg dose;this BFR had the longest tau (24.9 h).
Although the melatonin PRC was experimentally deter-
mined in sighted people,it appears to apply to blind peo-
ple as well. Currently, more is known about the phase-
advance zone of the melatonin PRC:for at least the second
half of the advance zone,the earlier melatonin is given,the
greater the magnitude of the phase-advance shift.When
melatonin is given daily to a free-running blind person,the
melatonin PRC will continue to drift later and later until
exogenous melatonin is hitting the point on the melatonin
PRC that will produce a phase advance equal to the daily
drift (this is called the entrainment point on the melatonin
PRC and will vary between individuals,depending in part
on the intrinsic tau).Then,the endogenous pacemaker will
lock on to the daily melatonin dose.For example,if a BFR’s
intrinsic circadian period,or tau,is 24.4 h,the melatonin
dose will stop the pacemaker from drifting later when it is
stimulating that part of the melatonin PRC when it pro-
Clinical research
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Figure 3. A totally blind subject with free-running circadian rhythms dur-
ing four trials of oral melatonin administration. Each data point
represents an assessment of circadian phase as determined by
successive measurements of the time that endogenous plasma
melatonin concentrations rose above the 10 pg/mL threshold.
Vertical lines represent the timing and duration of exogenous
melatonin administration. The slopes of the fitted regression
lines indicate circadian period (shown in hours beside the
regression lines) during a given treatment. The calculated cir-
cadian periods represent mean determinations between days
of assessment; fluctuation of circadian period probably occurs
as the melatonin dose stimulates different parts of the shifting
phase response curve (PRC). a. Baseline free-running circadian
rhythm of 24.92 h. b. Administration of 10 mg melatonin for
17 days beginning at CT 20.5 led to a shortened period of
24.34 h without entrainment. c. Administration of 9 to 10 mg
of melatonin over 83 days again failed to entrain this subject
but shortened circadian period to 24.36 h. d. Administration
of 20 mg initially at CT 14.6 shortened the subject’s circadian
period to 24.58 h after 60 days. e. Administration of 0.5 mg,
initially at CT 20.6, caused entrainment (circadian period of
23.98 h) after 47 days.
Reproduced from reference 92: Lewy AJ, Emens JS, Sack RL, Hasler BP,
Bernert RA. Low, but not high, doses of melatonin entrained a free-run-
ning blind person with a long circadian period. Chronobiol Int.
2002;19:649-658. Copyright © 2002, Marcel Dekker.
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96 72 48 24 0duces a phase advance of 0.4 h.Thus,entrainment occurs
and the pacemaker now functionally has a tau of 24.0 h.
The finding that low doses of melatonin may be more
effective than high doses,leading to the idea of avoiding
spillover, is illustrated in the treatment of the one BFR
who failed to entrain to the 10-mg dose (recall that he had
the longest tau,24.9 h,in that study).Despite repeat treat-
ment with 9 to 10 mg melatonin for 83 days and 20 mg
melatonin for 60 days (Figure 3),
92 he failed to entrain,
although his tau did shorten to 24.36 and 24.58 h,respec-
tively.He was finally entrained with 0.5 mg melatonin.
92
The melatonin PRC might explain why a lower dose of
melatonin is more effective than higher doses (Figure
4).
92While administering melatonin earlier in the advance
zone causes a greater phase advance and while higher
melatonin levels probably cause more of a phase advance
(perhaps by stimulating more of the phase-advance
zone),it appears that if the dose is too high,it will stim-
ulate more of the delay zone and therefore reduce the
magnitude of the phase advance.In other words,a lower
dose will have less “spillover” and might thus be more
effective than a higher dose.
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Figure 4. Pharmacokinetic data from two different melatonin doses (0.5 and 10 mg) in relation to the endogenous melatonin profile and the mela-
tonin phase response curve (PRC). The 0.5 mg dose and the endogenous melatonin profile are data from the subject in this study. The 10 mg
data were from another subject and were not collected beyond 10 h; it is clear that they cause more stimulation of the delay zone of the
melatonin PRC than the 0.5 mg dose. By convention, circadian time (CT) 14 is the endogenous melatonin onset (MO). In free-running sub-
jects, the endogenous melatonin profile and the melatonin PRC (which are phase-locked) drift later each day with respect to the sleep/wake
cycle. Normal phase is when the MO occurs 2 h before sleep onset (14 h after waketime). Exogenous melatonin causes phase advances when
it is given between CT 6 and CT 18 and causes phase delays when it is given between CT 18 and CT 6; however, the concentrations and
duration of exogenous melatonin levels as they spill over onto the wrong zone of the melatonin PRC may also affect the phase-shifting effect
of exogenous melatonin. 
Reproduced from reference 92: Lewy AJ, Emens JS, Sack RL, Hasler BP, Bernert RA. Low, but not high, doses of melatonin entrained a free-running blind per-
son with a long circadian period. Chronobiol Int. 2002;19:649-658. Copyright © 2002, Marcel Dekker.
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The endogenous melatonin profile and the melatonin shift later after each
day in a blind person with free-running rhythms, relative to clock time and sleep.
The melatonin onset (MO) occurs 2 h before
sleep, when the MO has drifted into the normal phase.The efficacy of low doses means that melatonin can be
administered well before sleep without causing daytime
or evening sleepiness. This is important, because the
treatment goal is not only entrainment,but also entrain-
ment at the optimal phase.Indeed,in the original study
of 10 mg,
87 successfully entrained BFRs had MOs occur-
ring after sleep onset, often much later (Figure 5).
93 In
other words, the MO occurred at the same time each
night, but later than normal.As in animal studies, the
greater the pretreatment free-running tau, the later
entrainment occurs relative to the time of the entraining
stimulus.In our entrained BFRs,their sleep disorders had
improved with treatment,but our subjects still had trou-
ble falling asleep and getting up in the morning.About
30% of people become sleepy on melatonin,and this side
effect appears to be dose-related and is troublesome at
doses greater than 1 mg, certainly at 10 mg. Now that 
0.5 mg has been shown to be an effective dose with min-
imal soporific side effects,it can be administered earlier
than bedtime (which is when the 10 mg was originally
given,in order to make use of this side effect).Melatonin
can be given earlier in the evening,so that the MO occurs
2 h before desired sleep time,thus resulting in optimal
sleep quality.
When shifting the clock time of exogenous melatonin
administration,the endogenous MO can be reset to any
time. Shifting the clock time of administration earlier
should be done gradually, so as not to cross over the
break point on the melatonin PRC.The clock time of
administration can also be shifted later, which can be
done in 1 day without loss of entrainment.In either case,
the pacemaker will shift with the time of the melatonin
dose.In blind people who appear to be entrained (or at
least have a tau virtually indistinguishable from 24.0 h)
to a behaviorally related zeitgeber or to ambient light
(perhaps in some blind people who are not bilaterally
enucleated),MOs can be reset earlier or later with a daily
dose of melatonin, so that the MO occurs 14 h after
waketime.
Several years ago,we also proposed that the abscissa and
ordinate of Figure 5 could be reversed.
94Accordingly,the
phase angle of entrainment could be used to predict tau.
While the taus of BFRs are probably the most accurate
estimate of the genetically programmed intrinsic tau
(which might be of use in studying clock genes in humans
95-
97),we also suggested that the DLMO ZT in sighted peo-
ple might be a useful way to estimate at least the func-
tional tau in people entrained to the light/dark cycle.
Melatonin treatment can be initiated 
at any time in BFRs
What would have happened if melatonin treatment were
initiated in BFRs on the “wrong”zone of the melatonin
PRC? In animal studies, it does not matter when the
entraining stimulus is given:eventually,the pacemaker is
stably entrained at a steady-state phase position,once the
entraining stimulus comes into contact with the entrain-
ment point of the PRC.
98 However,in a study published
a few years ago,the University of Surrey research group
found that they were able to entrain only about half of
their group of seven BRFs to a 5-mg dose of melatonin.
99
They noted that entrainment was successful only when
melatonin treatment was started on the advance zone of
the PRC,but not when treatment was started on the delay
zone, even if daily melatonin doses were continued
through a complete circadian beat cycle,so that eventually
melatonin stimulated all of the advance zone.They further
noted that this finding contradicted those of animal stud-
ies,in which starting a zeitgeber on the delay zone did not
affect its capability to eventually cause entrainment (it just
took longer before the entrainment point was reached as
the pacemaker, and the PRC, drifted into phase). If the
Surrey group is correct, this would mean that all BFRs
Clinical research
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Figure 5. Pretreatment tau predicts phase angle of entrainment (PAE).
PAE is the interval (in hours) between the time of the bedtime
10 mg melatonin dose and the entrained melatonin onset (MO)
of the endogenous melatonin profile. This figure is an updated
version of what has been previously reported, and the tau of
one person has been changed to 24.58 h from 24.63 h, cor-
recting an error in the previous report. The horizontal dotted
line indicates that entrainment will fail if the phase angle of
entrainment is more than 8 h.
Reproduced from reference 93: Lewy AJ, Hasler BP, Emens JS, Sack RL.
Pretreatment circadian period in free-running blind people may predict
the phase angle of entrainment to melatonin. Neurosci Lett.
2001;313:158-160. Copyright © 2001, Elsevier Science.
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P<0.05should have frequent MO assessments to determine on
what day melatonin treatment should be initiated.
Fortunately,this does not appear to be true.We found in
seven out of seven BFRs that when low-dose melatonin is
initiated on the delay zone,entrainment eventually occurs
when melatonin is given at the entrainment point in the
advance zone.
100The following case (Figure 6) using 0.05
mg is an example;in the other cases,a dose of 0.5 mg was
used.Recently,the Surrey group found that some BFRs
entrained when 0.5 mg was initiated on the delay zone;
however,they continue to recommend initiating melatonin
treatment on the advance zone.
Very low doses of melatonin are effective
in entraining BFRs
In this case (Figure 6),a very low dose (0.05 mg) of mela-
tonin was initiated in a BFR with a tau of 24.35 h on the
delay zone (CT 4.95). Initially, a clear increase in tau
occurred, consistent with a greater daily phase delay.
Within a few days,melatonin was stimulating the advance
zone and once the entrainment point was reached,the
pacemaker locked on.As mentioned above,low doses of
melatonin can usually entrain BFRs, no matter when
treatment is initiated.Therefore,at least for most blind
people,one does not need to start melatonin treatment
on the advance zone, although it may take longer to
reach the entrainment point when treatment begins on
the delay zone.The clinical implications of this finding
are very important:clinically,most blind people can be
treated without having to measure their endogenous cir-
cadian phase.Work is on-going to entrain BFRs to doses
of melatonin even lower than 0.05 mg.These doses pro-
duce peak melatonin levels that are less than what is
maximally produced endogenously.Melatonin can also
reset the phase of abnormally entrained blind people,
even under circumstances when they may be entraining
to a poorly perceived ambient light/dark cycle.
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Guidelines for treating CSDs in blind people
The above database provides a preliminary set of treat-
ment guidelines that should be effective in most blind
people with circadian sleep disorders (CSDs).However,
more studies need to be done,and there will clearly be
some blind people who will have to be assessed using the
MO for optimal treatment.
• Not every blind person has a CSD.Most,if not all,blind
people completely lacking in light perception have
CSDs,or at least merit treatment to prevent an even-
tual occurrence;however,the more light perception,the
more likely stable entrainment at a normal phase will
be the case.In any event,the first step is to take a sleep
history to determine whether the patient has DSPS or
ASPS, or sometimes has both that regularly recur,
which would suggest free-running circadian rhythms.If
possible, keeping a sleep diary—noting daily sleep
times,naps,nighttime sleep quality,and daytime alert-
ness—is advised;depressive symptoms may also occur
when there is a mismatch between circadian rhythms
and the sleep/wake cycle.
• Melatonin treatment should then be started.A dose of
0.5 mg at about 8.00 PM should result in entrainment of
BFRs and to optimal phase resetting in most blind peo-
ple.Stable steady-state entrainment at the normal phase
will take shorter or longer,depending on the tau and on
what day treatment was initiated.Although repeated
assessments of MOs can determine these parameters
with precision,they should not be necessary in most peo-
ple:eventually this treatment should be successful.If 3
months have passed without marked improvement,
referral to sleep a disorder center or some other facility
in which MOs can be assessed is advised.
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Figure 6. Blue circles represent an assessment of circadian phase as deter-
mined by the time that endogenous salivary melatonin concentrations
continuously rose above the 0.7 pg/mL threshold. Vertical lines represent
the timing and duration (days) of exogenous melatonin administration of
0.05 mg (black line) and 0.025 mg (gray line). All times are presented in
Pacific Standard Time (some times have been converted from Daylight
Saving Time).
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0 12 24 12 24 12• In a few individuals, the 0.5 mg dose may cause some
acute sleepiness.If unpleasant,the dose can be gradually
tapered every 2 weeks in increments of 0.1 mg to as low
as 0.1 mg,and then in increments of 0.025 mg to 0.05 mg,
if desired.However,for individuals who have longer taus,
the dose should not be reduced below 0.3 mg.Individuals
who report bouts of symptoms as often as every 4 to 6
weeks are likely to have longer taus (>24.6 h).
•After finding a suitable maintenance dose, the clock
time of administration can then be adjusted if the
patient still complains of symptoms of ASPS or DSPS.
When shifting the administration time earlier,advanc-
ing it no more than 30 min every 2 weeks should be suf-
ficiently conservative,so that the entrainment point will
not be crossed. Delaying a person with symptoms of
ASPS need not be done incrementally. However, in
either case shifting the clock time should be stopped
when sleep symptoms abate.
•These patients should probably remain on melatonin
treatment for the rest of their lives.Some minor shifts in
clock time of administration may be required. If not
taken daily,escape from steady-state entrainment at the
normal phase will likely occur.However,after the pace-
maker drifts through a complete cycle, the melatonin
dose should again capture the pacemaker at the optimal
phase.
•Although long-term studies of melatonin need to be
done,it is likely that doses of 0.5 mg or less (which result
in levels within the same order of magnitude as those
produced by the pineal) should be safe.To date,no seri-
ous, irreversible side effects have been unequivocally
linked to melatonin even at doses greater than 0.5 mg.
Nevertheless,we recommend that continuous melatonin
treatment be monitored by a physician or other respon-
sible caregiver,who is familiar with the most recent sci-
entific and medical literature.
Other circadian phase disorders
Research in SAD patients and blind people has helped
us understand how to treat circadian phase disorders and
syndromes in the general sighted population.These dis-
orders include ASPS and DSPS, jet lag, and shift work
maladaptation.All of these disorders and syndromes are
to a greater or lesser extent related to the circadian tim-
ing system and can be phase typed,according to whether
they are phase delayed or phase advanced (Table I).
Treatment of these disorders is based on the light and
melatonin PRCs.
44To provide a corrective phase advance,
bright light should be scheduled immediately upon awak-
ening in the morning and melatonin should be taken in
the afternoon/evening. To provide a corrective phase
delay,bright light should be scheduled in the evening and
melatonin should be taken in the morning.
Delayed sleep phase syndrome
Melatonin and light are both effective in treating
DSPS.
102,103 The first published report of treating DSPS
with light was in 1983.
33This topic is reviewed elsewhere.
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Most people with DSPS are younger and prefer to sleep
late in the morning,having difficulty falling asleep until
as late as 4.00 AM.These individuals can be treated by
scheduling their waketimes to occur gradually earlier
(perhaps 15 min every other day) until the desired wake-
time is reached.Going outdoors immediately upon awak-
ening for about 30 min will help advance the circadian
rhythm of sleep propensity,as will taking 0.5 mg of mela-
tonin about 8 h after waketime. One or both of these
treatments may be necessary to hold the sleep/wake cycle
to the desired time.If outdoor sunlight is not available or
inconvenient,a portable fixture may be used for 30 to 60
min;the fixture should be at a distance from the eyes so
that the intensity is about 10 000 lux. Research on the
most potent wavelengths for phase shifting and melatonin
suppression may eventually result in some modification
of light sources.In the US,melatonin is widely available.
If the dose of 0.5 mg happens to cause sleepiness in an
individual who is unusually sensitive to this side effect,it
should be decreased and a repeat dose should be given
a few hours later.For individuals who become sleepy on
(usually higher doses of) melatonin,1 to 3 mg at bedtime
may be usefully taken to induce sleep.
Advanced sleep phase syndrome
ASPS generally occurs in older individuals,who tire early
in the evening and wake up as early as 4.00 AM.The first
reference to treating ASPS with light was published in
1985.
105This subject is reviewed elsewhere.
104Treatment rec-
ommendations include 1 to 2 h of 10 000 lux exposure in
the evening, ending at least 1 h before desired bedtime.
Melatonin (0.5 mg) should be taken at each awakening
and upon final arising in the morning.Whenever melatonin
is taken during waketime,people should not drive if they
feel sleepy and lowering the dose should be considered.
Clinical research
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Although sleep deprivation resulting from flying at night
contributes to the malaise following air travel,there is lit-
tle doubt that jet lag is caused by a mismatch between
circadian rhythms that are tightly coupled to the endoge-
nous circadian pacemaker and destination sleep/wake
time. A good rule of thumb is that it takes 1 day to
recover from every time zone crossed, with the caveat
that jet lag is usually worse when traveling east than
when traveling west.
There have been numerous studies of light and melatonin
in the amelioration of jet lag.These have been recently
reviewed.
106,107The first study to test the effect of light on
jet lag was published in 1984.
108The first study to test the
effect of melatonin on jet lag was published in 1986.
109 On
the whole,both have been shown to be somewhat effica-
cious.However,optimal testing of melatonin in the treat-
ment of jet lag has not yet occurred.For example,no peer-
reviewed report has included taking 0.5 mg melatonin in
the afternoon before traveling east or in the morning
before traveling west,which is what we recommend should
be done for up to 2 days before travel,as well as on the
day of travel.Taking melatonin at destination is more com-
plicated.After traveling across more than five time zones,
melatonin can be taken at bedtime. However, as the
endogenous circadian pacemaker adjusts to local time,
bedtime may not be the best time—and may even be the
wrong time—to take melatonin (see below).
Bright light exposure is not convenient to schedule before
travel.At destination,obtaining sunlight exposure at the
correct time can greatly facilitate circadian realignment.
Even more important, particularly after crossing more
than five time zones,is avoiding sunlight exposure at the
wrong time,which will shift circadian rhythms in the direc-
tion opposite to that traveled. When flying from Los
Angeles to Madrid, for example, it would take several
more days to delay the body clock 15 h than to advance it
9 h.(However,extreme night owls might prefer to delay
their clocks no matter which direction of travel.) 
Precise recommendations for obtaining and avoiding
sunlight at destination depend on what are thought to be
the light PRC’s break points.The following recommen-
dations are based on a light PRC with the break points
at CT 6 and CT 18,using the beginning of the light pulse
as its phase reference. Using the middle of a relatively
long bout of bright light exposure as the phase reference,
which is done in most human (but not animal) studies,
would put these break points a few hours later;however,
this requires people to schedule long periods of (prefer-
ably bright) light exposure.Furthermore,a recent study
indicates that the beginning of the light pulse is its most
powerful part, at least with respect to causing phase
advances.
After traveling across five or fewer time zones,start sun-
light exposure as early as possible in the morning after
going east or as late as possible in the afternoon after
going west.After traveling across six or more time zones,
obtain sunlight exposure in the middle of the day and
avoid it in the morning after going east or at the end of
the day after going west.On subsequent days,these times
can be shifted,as if one had traveled through fewer time
zones (see below).
Using both light and melatonin at the optimal times,it is
reasonable to assume a rate of phase shifting of 3 h per
day.For example,after traveling nine time zones to the
east, a person who habitually arises at 7.00 AM should
avoid sunlight exposure before 10.00 AM and obtain at
least 30 min of it shortly after this time.The next day sun-
light exposure should occur shortly after 7.00 AM.
Melatonin should be taken at 2.00 PM before travel and
at 11.00 PM upon reaching the destination.It should then
be taken 3 h earlier each day until it is again taken at 2.00
PM for a couple of days.After traveling nine time zones
to the west,take melatonin at 10.00 PM the first night,but
on subsequent nights it should be taken only if awake
after 1.00 AM and then again upon final awakening in the
morning.
After traveling six or more time zones to the west,bright
light should be avoided at the end of the day and sunlight
should be obtained in the middle of the day.After 1 or
2 days,bright light should be obtained at the end of the
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Table I. Phase typing for circadian rhythm disorders.
• Phase-advanced type • Phase-delayed type
Advanced sleep phase syndrome (ASPS) Delayed sleep phase syndrome (DSPS)
East-to-west jet lag West-to-east jet lag
Night work maladaptation (work days) Night work maladaptation (weekends)
Typical seasonal affective disorder (SAD)day.Melatonin can be taken at bedtime the first night at
destination,but should not be taken before 1.00 AM on
subsequent days, except under special circumstances.
Optimal scheduling of light and melatonin depends on
the habitual waketime of an individual,the direction of
travel, the number of time zones crossed, and the pre-
sumed rate of phase shifting.A complete table of instruc-
tions would be helpful and will hopefully be available
soon.We recommend taking the lowest dose of mela-
tonin currently available or using a pill cutter.In a few
people,even the 0.5 mg dose may cause sleepiness imme-
diately after taking it during the day.Lowering the dose
further will reduce the soporific side effect, but then a
second dose should be taken a few hours later,particu-
larly when a phase advance is desired,in order to create
overlap between the exogenous melatonin pulse and the
endogenous melatonin profile,as described above.
Shift work maladaptation
Although it is quite clear that very few shift workers
adapt their circadian rhythms to conform to their work
schedules,there is no consensus as to how best to help
them.This topic has been reviewed elsewhere.The first
use of light to treat shift workers was published in 1987.
110
The first use of melatonin to treat shift workers was pub-
lished in the early 1990s.
111,112When trying to sleep at odd
hours,shift workers have a type of jet lag.Night workers
have the same problems as someone who has traveled
through 12 time zones,in fact,worse,since air travelers
usually adjust at a rate of at least 1 h per day, as men-
tioned above.Night workers rarely adjust their circadian
rhythms,probably because of the morning sunlight expo-
sure that occurs on the way home from work.Evening
workers have it somewhat easier.Chronobiologists uni-
formly recommend staying on the same schedule every
day,week after week.Neither light nor melatonin would
then be necessary. However, workers (certainly those
who do so at night) are uniformly against sleeping dur-
ing the day on their weekends.Because their circadian
rhythms do not usually adapt to their work schedules,
shift workers feel good only on their days off.After work-
ing each night,they force themselves to sleep during the
day when their body clocks would have them stay up,and
of course their work suffers as they soldier through the
wee hours of the night when their body clock would have
them sleep. A number of medical complaints often
accompany shift work,and the older one gets,the harder
it is to adapt.
Experts do not agree on how to help shift workers.As
mentioned above,part of the problem lies in the fact that
some workers would rather feel better on their days off
than on their workdays,while managers understandably
want workers to be most rested and alert during their
hours of employment.Even if this issue is resolved,the
next conundrum is that one cannot shift more than 3 to
4 h per day.
Compromise schedules that rely on the use of appropri-
ately timed bright light and/or melatonin administration
have been proposed that stabilize circadian phase midway
between work and off-work schedules. For example,
Eastman and associates have proposed such a compromise
schedule.
113We are in the process of developing our own
version of a compromise schedule,but its implementation
may depend on the development of delayed-release mela-
tonin formulations that are not yet available. ❏
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Experiencia clínica con melatonina en los
trastornos circadianos
Los síndromes y trastornos cronobiológicos incluyen
el trastorno afectivo estacional (TAE), la ceguera
total, los síndromes de avance y retraso de fases del
sueño, el jet lag y la mala adaptación a los turnos
laborales. Estos trastornos se tratan ajustando las
fases circadianas, mediante la utilización de un
tiempo apropiado de exposición a la luz brillante y
la administración de melatonina (en dosis de 0,5 mg
o menos). En algunos casos puede ser necesario
medir las fases circadianas internas utilizando el
período en que se elevan los niveles de melatonina
endógena.
Applications cliniques de la mélatonine dans
les troubles circadians
Les syndromes et troubles chronobiologiques
regroupent le trouble affectif saisonnier (TAS), les
desordres entraînés par la cécité totale, les syn-
dromes type retard ou avance de phase, les symp-
tômes liés aux changements de fuseaux horaires (jet
lag), et les perturbations dues au travail posté. Ces
troubles sont traités en réajustant le rythme circa-
dien, grâce à l’utilisation judicieuse et minutée de
l’exposition à la lumière brillante et à l’administra-
tion de mélatonine (0,5 mg ou moins). Parfois, il
semble nécessaire de mesurer le rythme circadien
interne, au moment de l’élévation des concentra-
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